Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Verrica Pharmaceuticals Inc (NQ: VRCA ) 2.300 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 239 Open 2.300 Bid (Size) 2.280 (2) Ask (Size) 2.490 (4) Prev. Close 2.300 Today's Range 2.300 - 2.300 52wk Range 2.021 - 11.41 Shares Outstanding 41,957,197 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York September 04, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month August 27, 2024 Via Benzinga Performance YTD -66.23% -66.23% 1 Month -58.18% -58.18% 3 Month -74.86% -74.86% 6 Month -53.72% -53.72% 1 Year -47.13% -47.13% More News Read More Crude Oil Down Over 1%; Mercury Systems Shares Spike Higher August 14, 2024 Via Benzinga Exposures Fossil Fuels Dow Jumps Over 200 Points; Performance Food Group Shares Gain After Q4 Results August 14, 2024 Via Benzinga Topics Stocks Exposures US Equities VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 August 14, 2024 Via InvestorPlace US Stocks Mixed; Inflation Rate Falls More Than Projected August 14, 2024 Via Benzinga Topics Economy Exposures Interest Rates Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday? August 14, 2024 Via Benzinga Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results August 14, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma August 14, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024 August 06, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire 7 Short-Squeeze Stocks That Could Beat Down the Bears July 15, 2024 Via InvestorPlace Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc. July 01, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York May 30, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm May 26, 2024 From Bragar Eagel & Squire Via GlobeNewswire VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm May 17, 2024 From Bragar Eagel & Squire Via GlobeNewswire Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts May 15, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Planet Fitness To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday May 14, 2024 Via Benzinga VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 May 13, 2024 Via InvestorPlace Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results May 13, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals to Present at Upcoming Investor Conferences May 09, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024 May 08, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm April 27, 2024 From Bragar Eagel & Squire Via GlobeNewswire Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference April 02, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA March 26, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA March 08, 2024 From Kahn Swick & Foti, LLC Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
